Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis. / Lerche, C. J.; Christophersen, L. J.; Trøstrup, H.; Thomsen, K.; Jensen, Peter Østrup; Hougen, H. P.; Bundgaard, H.; Høiby, N.; Moser, C.

In: European Journal of Clinical Microbiology & Infectious Diseases, Vol. 34, No. 12, 01.12.2015, p. 2349-2357.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lerche, CJ, Christophersen, LJ, Trøstrup, H, Thomsen, K, Jensen, PØ, Hougen, HP, Bundgaard, H, Høiby, N & Moser, C 2015, 'Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis', European Journal of Clinical Microbiology & Infectious Diseases, vol. 34, no. 12, pp. 2349-2357. https://doi.org/10.1007/s10096-015-2488-5

APA

Lerche, C. J., Christophersen, L. J., Trøstrup, H., Thomsen, K., Jensen, P. Ø., Hougen, H. P., Bundgaard, H., Høiby, N., & Moser, C. (2015). Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis. European Journal of Clinical Microbiology & Infectious Diseases, 34(12), 2349-2357. https://doi.org/10.1007/s10096-015-2488-5

Vancouver

Lerche CJ, Christophersen LJ, Trøstrup H, Thomsen K, Jensen PØ, Hougen HP et al. Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis. European Journal of Clinical Microbiology & Infectious Diseases. 2015 Dec 1;34(12):2349-2357. https://doi.org/10.1007/s10096-015-2488-5

Author

Lerche, C. J. ; Christophersen, L. J. ; Trøstrup, H. ; Thomsen, K. ; Jensen, Peter Østrup ; Hougen, H. P. ; Bundgaard, H. ; Høiby, N. ; Moser, C. / Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis. In: European Journal of Clinical Microbiology & Infectious Diseases. 2015 ; Vol. 34, No. 12. pp. 2349-2357.

Bibtex

@article{6d81fd10594b43aa8fc0627c326e397f,
title = "Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis",
abstract = "The empiric treatment of infective endocarditis (IE) varies widely and, in some places, a regimen of penicillin in combination with an aminoglycoside is administered. The increasing incidence of Staphylococcus aureus IE, poor tissue penetration by aminoglycosides and low frequency of penicillin-susceptible S. aureus may potentially lead to functional tobramycin monotherapy. Therefore, this study aimed to evaluate tobramycin monotherapy in an experimental S. aureus IE rat model. Catheter-induced IE at the aortic valves were established with S. aureus (NCTC 8325-4) and rats were randomised into untreated (n = 22) or tobramycin-treated (n = 13) groups. The treatment group received tobramycin once-daily. Animals were evaluated at 1 day post infection (DPI), 2 DPI or 3 DPI. Quantitative bacteriology and cytokine expression were measured for valves, myocardium and serum. A decrease of bacterial load was observed in valves and the spleens of the treated (n = 6) compared to the untreated group at 2 DPI (n = 8) (p ≤ 0.02 and p ≤ 0.01, respectively), but not at 3 DPI (n = 7). Quantitative bacteriology in the myocardium was not different between the groups. Keratinocyte-derived chemokine (KC) in the aortic valves was significantly reduced at 2 DPI in the tobramycin-treated group (p ≤ 0.03). However, the expression of interleukin (IL)-1b, IL-6 and granulocyte-colony stimulating factor (G-CSF) in the valves was not different between the two groups. In the myocardium, a significant reduction in IL-1b was observed at 2 DPI (p ≤ 0.001) but not at 3 DPI. Tobramycin as functional monotherapy only reduced bacterial load and inflammation transiently, and was insufficient in most cases of S. aureus IE.",
author = "Lerche, {C. J.} and Christophersen, {L. J.} and H. Tr{\o}strup and K. Thomsen and Jensen, {Peter {\O}strup} and Hougen, {H. P.} and H. Bundgaard and N. H{\o}iby and C. Moser",
year = "2015",
month = dec,
day = "1",
doi = "10.1007/s10096-015-2488-5",
language = "English",
volume = "34",
pages = "2349--2357",
journal = "European Journal of Clinical Microbiology & Infectious Diseases",
issn = "0934-9723",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis

AU - Lerche, C. J.

AU - Christophersen, L. J.

AU - Trøstrup, H.

AU - Thomsen, K.

AU - Jensen, Peter Østrup

AU - Hougen, H. P.

AU - Bundgaard, H.

AU - Høiby, N.

AU - Moser, C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The empiric treatment of infective endocarditis (IE) varies widely and, in some places, a regimen of penicillin in combination with an aminoglycoside is administered. The increasing incidence of Staphylococcus aureus IE, poor tissue penetration by aminoglycosides and low frequency of penicillin-susceptible S. aureus may potentially lead to functional tobramycin monotherapy. Therefore, this study aimed to evaluate tobramycin monotherapy in an experimental S. aureus IE rat model. Catheter-induced IE at the aortic valves were established with S. aureus (NCTC 8325-4) and rats were randomised into untreated (n = 22) or tobramycin-treated (n = 13) groups. The treatment group received tobramycin once-daily. Animals were evaluated at 1 day post infection (DPI), 2 DPI or 3 DPI. Quantitative bacteriology and cytokine expression were measured for valves, myocardium and serum. A decrease of bacterial load was observed in valves and the spleens of the treated (n = 6) compared to the untreated group at 2 DPI (n = 8) (p ≤ 0.02 and p ≤ 0.01, respectively), but not at 3 DPI (n = 7). Quantitative bacteriology in the myocardium was not different between the groups. Keratinocyte-derived chemokine (KC) in the aortic valves was significantly reduced at 2 DPI in the tobramycin-treated group (p ≤ 0.03). However, the expression of interleukin (IL)-1b, IL-6 and granulocyte-colony stimulating factor (G-CSF) in the valves was not different between the two groups. In the myocardium, a significant reduction in IL-1b was observed at 2 DPI (p ≤ 0.001) but not at 3 DPI. Tobramycin as functional monotherapy only reduced bacterial load and inflammation transiently, and was insufficient in most cases of S. aureus IE.

AB - The empiric treatment of infective endocarditis (IE) varies widely and, in some places, a regimen of penicillin in combination with an aminoglycoside is administered. The increasing incidence of Staphylococcus aureus IE, poor tissue penetration by aminoglycosides and low frequency of penicillin-susceptible S. aureus may potentially lead to functional tobramycin monotherapy. Therefore, this study aimed to evaluate tobramycin monotherapy in an experimental S. aureus IE rat model. Catheter-induced IE at the aortic valves were established with S. aureus (NCTC 8325-4) and rats were randomised into untreated (n = 22) or tobramycin-treated (n = 13) groups. The treatment group received tobramycin once-daily. Animals were evaluated at 1 day post infection (DPI), 2 DPI or 3 DPI. Quantitative bacteriology and cytokine expression were measured for valves, myocardium and serum. A decrease of bacterial load was observed in valves and the spleens of the treated (n = 6) compared to the untreated group at 2 DPI (n = 8) (p ≤ 0.02 and p ≤ 0.01, respectively), but not at 3 DPI (n = 7). Quantitative bacteriology in the myocardium was not different between the groups. Keratinocyte-derived chemokine (KC) in the aortic valves was significantly reduced at 2 DPI in the tobramycin-treated group (p ≤ 0.03). However, the expression of interleukin (IL)-1b, IL-6 and granulocyte-colony stimulating factor (G-CSF) in the valves was not different between the two groups. In the myocardium, a significant reduction in IL-1b was observed at 2 DPI (p ≤ 0.001) but not at 3 DPI. Tobramycin as functional monotherapy only reduced bacterial load and inflammation transiently, and was insufficient in most cases of S. aureus IE.

U2 - 10.1007/s10096-015-2488-5

DO - 10.1007/s10096-015-2488-5

M3 - Journal article

C2 - 26440039

AN - SCOPUS:84947866621

VL - 34

SP - 2349

EP - 2357

JO - European Journal of Clinical Microbiology & Infectious Diseases

JF - European Journal of Clinical Microbiology & Infectious Diseases

SN - 0934-9723

IS - 12

ER -

ID: 160026103